This topic contains a solution. Click here to go to the answer

Author Question: Will a perfectly competitive firm ever produce in the short run even though it is incurring an ... (Read 41 times)

jparksx

  • Hero Member
  • *****
  • Posts: 570
Will a perfectly competitive firm ever produce in the short run even though it is incurring an economic loss?
 
  What will be an ideal response?

Question 2

When long-run average cost increases as output increases there are
 
  A) economies of scale.
  B) diseconomies of scale.
  C) constant returns to scale.
  D) none of the above.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

juicepod

  • Sr. Member
  • ****
  • Posts: 310
Answer to Question 1

Yes, a perfectly competitive firm will continue to produce even though it is suffering an economic loss if the price exceeds the minimum average variable cost. In this case, even though the firm has an economic loss, if it shut down, its economic loss would be larger.

Answer to Question 2

B




jparksx

  • Member
  • Posts: 570
Reply 2 on: Jun 29, 2018
Excellent


6ana001

  • Member
  • Posts: 311
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

HIV testing reach is still limited. An estimated 40% of people with HIV (more than 14 million) remain undiagnosed and do not know their infection status.

Did you know?

Human neurons are so small that they require a microscope in order to be seen. However, some neurons can be up to 3 feet long, such as those that extend from the spinal cord to the toes.

Did you know?

Most fungi that pathogenically affect humans live in soil. If a person is not healthy, has an open wound, or is immunocompromised, a fungal infection can be very aggressive.

Did you know?

Oxytocin is recommended only for pregnancies that have a medical reason for inducing labor (such as eclampsia) and is not recommended for elective procedures or for making the birthing process more convenient.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library